

DISCLOSURE OF TRANSFERS OF VALUE TO RECIPIENTS IN THE UNITED KINGDOM IN 2024

METHODOLOGICAL NOTE

General summary

Octapharma Limited documents and declares transfers of value made by the company and its affiliates to health professionals, other relevant decision makers, health organisations, and relevant third parties within the United Kingdom (UK). Details of transfers to recipients in the UK in the calendar year 2024 are provided at the central platform for disclosure provided by the Association of the British Pharmaceutical Industry (ABPI).

Recognition methodologies applied

Transfers of value qualifying for disclosure are identified during a payment review process. Each transfer of value is allocated to one of the value categories defined by the ABPI. Transfers of value to individuals are aggregated on a category-by-category basis. Transfers of value to organisations are disclosed on a per activity basis.

Indirect transfers of value to an individual via an organisation are allocated to the individual if the identity of the individual is known. If the identity of an individual is not known, the transfer is allocated to the organisation.

If the identity of an individual cannot be disclosed for legal reasons, the transfer of value is instead disclosed as part of an anonymised aggregate figure. The number of individuals within the aggregate is also disclosed, together with the percentage of all recipients that they represent.

Transfers of value for research and development made to individuals and organisations are disclosed as part of an anonymised aggregate figure for research and development.

Multi-year contracts

Transfers of value are disclosed according to the date of transfer from Octapharma. Only value transferred by Octapharma in 2024 appears in the 2024 disclosure information.

Currency and VAT

Where a transfer has been made in a currency other than the Great British Pound (GBP), the GBP equivalent has been determined using the average monthly exchange rate at the date of data preparation. Where VAT is charged, the total amount including VAT is disclosed.

Timing of transfers of value

Following a request for a transfer of value, transfers are made according to the usual practices of Octapharma's Finance Departments.

Aggregation of transfers of value

There were no partial disclosures i.e. instances where one or more transfers to an individual were disclosed individually and one or more transfers to that individual were disclosed in aggregate.

End

Clare Worden MBA
General Manager
Octapharma Limited
26 March 2025

Octapharma Limited
The Zenith Building
26 Spring Gardens
Manchester
M2 1AB

Office: +44 (0)161 837 3770
Fax: +44 (0)161 837 3799
Email: octapharma@octapharma.co.uk
Web: www.octapharma.co.uk